Ascendis Pharma A/S (ASND)
A+
Pipeline Grade
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
NAVEPEGRITIDE
YUVIWEL |
APPROVED | 2L+ Cervical Cancer, Achondroplasia, Adult Growth Hormone Deficiency, Advanced Solid Tumor, Endocrine System Diseases, Growth Hormone Deficiency (GHD), Growth Hormone Deficiency, Pediatric, Growth Hormone-Deficiency, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma HNSCC, Healthy, Healthy Volunteers, hGH (Human Growth Hormone), Hormone Deficiency, Hormones, HPV-associated Cancers, Hypoparathyroidism, Idiopathic Short Stature, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC), Neoadjuvant Melanoma, Neoadjuvant Non-Small Cell Lung Cancer, Parathyroid Diseases, Pituitary Disease, Anterior, Pituitary Diseases, Platinum-resistant Ovarian Cancer, Post Anti-PD-(L)1 Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Small Cell Lung Cancer, Post Anti-PD-1 Melanoma, Second or Third Line (2L/3L) Cervical Cancer, Short Stature Homeobox Gene Mutation, Small for Gestational Age at Delivery, Third Line or Later (3L+) HER2+ Breast Cancer, Third-line or Later ( |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-06-01 | Phase3 Readout | — |
Active Clinical Trials (12)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07264634 | A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegte... | OTHER | Recruiting | 10 |
| NCT05820672 | A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA | OTHER | Recruiting | 900 |
| NCT05775523 | A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin | OTHER | Recruiting | 500 |
| NCT07345494 | A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegter... | OTHER | Recruiting | 50 |
| NCT07081997 | A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than ... | PHASE3 | Recruiting | 36 |
| NCT07221851 | Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Ado... | PHASE3 | Recruiting | 186 |
| NCT05929807 | A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon ... | PHASE3 | Enrolling By Invitation | 140 |
| NCT05690386 | A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome | PHASE2 | Active Not Recruiting | 48 |
| NCT06732895 | A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondropla... | PHASE2 | Recruiting | 24 |
| NCT06433557 | A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsoma... | PHASE2 | Active Not Recruiting | 22 |
| NCT06079398 | A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age)... | PHASE2 | Recruiting | 72 |
| NCT05081609 | A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or ... | PHASE2 | Active Not Recruiting | 320 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.